Summary of Senti Biosciences FY Conference Call Company Overview - **Company**: Senti Biosciences (NasdaqCM:SNTI) - **Lead Program**: Senti 202, an off-the-shelf allogeneic CAR NK cell therapy targeting acute myeloid leukemia (AML) [2][3][31] Industry Context - **Focus Area**: Oncology, specifically targeting cancer cells while sparing healthy cells - **Challenge**: Many cancers lack a single target that is unique to cancer cells, complicating treatment options [2][5][33] Core Technology - **Logic Gate Technology**: Utilizes a NOT gate mechanism to protect healthy cells while targeting cancer cells [4][39] - **Targets**: Senti 202 targets CD33 and FLT3, which are expressed in over 95% of AML patients [9][38] Clinical Development - **Current Phase**: Phase 1 dose expansion study, actively enrolling patients [3][40] - **Patient Population**: Focus on relapsed/refractory AML patients, with a disease burden of approximately 20,000 patients per year in the U.S. [6][34] - **Efficacy Data**: Preliminary data shows an overall response rate (ORR) of 71% in evaluable patients, with 57% achieving a composite complete response (CR) [15][45] Safety Profile - **Adverse Events**: Generally well tolerated with no serious adverse events (SAEs) or dose-limiting toxicities (DLTs) attributed to Senti 202 [43][44] - **Lymphodepletion Effects**: Expected drop in healthy blood cell counts post-lymphodepletion, followed by recovery [14][50] Future Outlook - **Upcoming Data**: Additional phase 1 data expected by the end of the year, with a focus on durability and correlative data using CyTOF analyses [26][59] - **Expansion Potential**: Opportunities to apply logic gate technology to newly diagnosed AML, myelodysplastic syndromes (MDS), and solid tumors [21][52] Key Takeaways - **Unmet Need**: Significant opportunity exists in the relapsed/refractory AML space, especially for patients who do not qualify for existing therapies [35][36] - **Regulatory Pathway**: Potential for FDA breakthrough designation based on precedents set by other therapies in the same space [52] - **Technology Versatility**: Logic gate technology may be adapted for various cancer types, enhancing treatment specificity and efficacy [22][56] Conclusion - Senti Biosciences is positioned to make significant advancements in the treatment of AML through its innovative logic gate technology, with promising early clinical data and a clear path for future development [20][24]

Core Insights - Senti Biosciences, Inc. is set to present at Chardan's 9th Annual Genetic Medicines Conference on October 21, 2025, in New York, NY [1] - The company is focused on developing next-generation cell and gene therapies using its proprietary Gene Circuit platform [1][3] - Management will also engage in one-on-one meetings with qualified investors during the conference [2] Company Overview - Senti Bio is a clinical-stage biotechnology company targeting incurable diseases through innovative cell and gene therapies [3] - The company utilizes a synthetic biology platform to engineer Gene Circuits aimed at precisely targeting and killing cancer cells while sparing healthy cells [3] - Senti Bio's pipeline includes cell therapies designed for challenging liquid and solid tumor indications, with preclinical evidence supporting the efficacy of Gene Circuits in NK and T cells [3] Additional Information - Investors and the public can access more information about Senti Bio through its website and social media platforms [4] - The company emphasizes the importance of its online communications for investor relations and public disclosures [4]

Core Insights - Senti Biosciences, Inc. will present at BioJapan on October 9, 2025, showcasing its innovative Gene Circuit platform for cell and gene therapies [1] - The presentation will be led by CEO Timothy Lu, and the company will also engage in one-on-one meetings with investors during the conference [1] - BioJapan is recognized as Asia's leading bio-industry partnering event, promoting collaboration and innovation in biotechnology [3] Company Overview - Senti Bio focuses on developing next-generation cell and gene therapies aimed at treating incurable diseases through its proprietary synthetic biology platform [4] - The company's Gene Circuits are engineered to selectively target and kill cancer cells while sparing healthy cells, enhancing treatment specificity and control [4] - Senti Bio's pipeline includes therapies targeting both liquid and solid tumors, with preclinical evidence supporting the efficacy of its Gene Circuits in NK and T cells [4]

Summary of Senti Biosciences Conference Call Company Overview - **Company**: Senti Biosciences (NasdaqCM:SNTI) - **Industry**: Biotechnology, specifically focused on cell therapy Core Points and Arguments 1. **Logic-Gated Cell Therapy**: Senti Biosciences specializes in logic-gated cell therapy, which allows engineered cells to perform multiple functions based on various inputs from the host cell [1][2] 2. **Lead Program - SENTI-202**: The lead program, SENTI-202, is a first-in-class therapy targeting acute myeloid leukemia (AML), particularly affecting individuals aged 65 and older [2][5] 3. **Orphan Drug Designation**: SENTI-202 has received orphan drug designation, indicating its potential to address a significant unmet medical need in AML [2] 4. **Clinical Trial Progress**: Positive preliminary efficacy data has been demonstrated in the ongoing phase 1 clinical trial, with additional data expected by the end of the year [2][5] 5. **AML Statistics**: Approximately 20,000 to 21,000 Americans are diagnosed with AML annually, with a median survival of 5.3 months for those who do not respond to first-line therapy [5][6] 6. **Challenges in AML Treatment**: The heterogeneity of AML and the presence of therapy-resistant leukemic stem cells (LSCs) pose significant challenges in developing effective therapies [7][8] 7. **Mechanism of Action**: SENTI-202 utilizes a unique logic gate mechanism to selectively kill AML cells while sparing healthy cells, addressing the issue of shared targets between LSCs and healthy hematopoietic stem cells [9][11] 8. **NK Cell Utilization**: The therapy employs natural killer (NK) cells, which can be used across different patients without the risk of graft-versus-host disease, and have shown a response rate of about 20% in non-engineered forms [10][15] 9. **Efficacy Data**: In the RP2D cohort, 67% of patients achieved complete remission (CR), with 100% being measurable residual disease (MRD) negative, indicating a strong response to treatment [18][19] 10. **Safety Profile**: The safety profile of SENTI-202 is favorable, with no grade 3 adverse events reported and manageable infusion-related reactions [18][21] Additional Important Content 1. **Gene Circuit Design**: The gene circuit in SENTI-202 includes an OR logic gate for targeting multiple antigens and a NOT logic gate to protect healthy cells from being killed [11][13] 2. **Manufacturing Process**: The manufacturing process for SENTI-202 is off-the-shelf, allowing for immediate shipment of cells upon patient approval, which enhances operational efficiency [14] 3. **Future Plans**: The company plans to confirm the recommended phase 2 dose (RP2D) and expand the patient cohort, with further data presentation anticipated by the end of the year [21][22] This summary encapsulates the key points discussed during the conference call, highlighting Senti Biosciences' innovative approach to treating AML through its SENTI-202 program and the promising data emerging from its clinical trials.

Company Overview - Senti Biosciences, Inc. is a clinical-stage biotechnology company focused on developing next-generation cell and gene therapies using its proprietary Gene Circuit platform [2] - The company aims to create new medicines that can precisely target and kill cancer cells while sparing healthy cells, enhancing specificity to target tissues, and allowing for control even after administration [2] Upcoming Presentation - Kanya Rajangam, M.D., Ph.D., President, Head of Research & Development and Chief Medical Officer of Senti, will present at the MedInvest Biotech & Pharma Conference on September 24, 2025, at 9:55 AM PT [1] - A live webcast of the presentation will be available on the company's website [2] Investor Engagement - Management will be available for one-on-one meetings with qualified members of the investor community registered for the conference [2] - The company encourages investors and the public to review information posted on its website and social media platforms regularly [3]

Core Insights - Senti Biosciences, Inc. is a clinical-stage biotechnology company focused on developing next-generation cell and gene therapies using its proprietary Gene Circuit platform [1][3] - The company will present at the H.C. Wainwright 27th Annual Global Investment Conference on September 8, 2025, at 2:00 PM ET [1] - Senti Bio's Gene Circuits are engineered to target cancer cells while sparing healthy cells, enhancing specificity, and allowing for post-administration control [3] Company Overview - Senti Bio is dedicated to creating new medicines for patients with incurable diseases through its synthetic biology platform [3] - The company's pipeline includes cell therapies designed to address challenging liquid and solid tumor indications [3] - Preclinical studies have shown the effectiveness of Senti's Gene Circuits in both NK and T cells, with potential applications beyond oncology [3] Investor Engagement - Management will be available for in-person one-on-one meetings with qualified investors during the conference [2] - A live video webcast of the presentation will be accessible on the company's website, with a replay available for 90 days [2]

Company Overview - Senti Biosciences, Inc. is a clinical-stage biotechnology company focused on developing next-generation cell and gene therapies using its proprietary Gene Circuit platform [1][3] - The company aims to create new medicines that can precisely target and kill cancer cells while sparing healthy cells, enhancing specificity to target tissues, and allowing for control even after administration [3] Upcoming Presentation - Senti Bio will present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech on August 19, 2025, at 2:20 PM ET [1] - The presentation will be led by Timothy Lu, M.D., Ph.D., Co-Founder and CEO of Senti Bio [1] Technology and Pipeline - Senti Bio's pipeline includes cell therapies engineered with Gene Circuits targeting challenging liquid and solid tumor indications [3] - The Gene Circuits have shown preclinical efficacy in both NK and T cells, with potential applications extending beyond oncology [3]

Core Insights - Senti Biosciences, Inc. is a clinical-stage biotechnology company focused on developing next-generation cell and gene therapies using its proprietary Gene Circuit platform [2][4] - The company recently announced the recommended Phase 2 dose selection for its first-in-class Logic Gated off-the-shelf CAR-NK cell therapy, SENTI-202, aimed at treating relapsed/refractory hematologic malignancies, including acute myeloid leukemia (AML) [3] Company Overview - Senti Bio is leveraging synthetic biology to engineer Gene Circuits that enhance precision and control in new medicines, specifically targeting cancer cells while sparing healthy cells [4] - The company's pipeline includes cell therapies designed to address challenging liquid and solid tumor indications, with preclinical evidence supporting the efficacy of Gene Circuits in both NK and T cells [4] Recent Developments - The participation in the Virtual Investor segment highlights the company's ongoing efforts to communicate its advancements and strategies to potential investors [2][3] - The focus on SENTI-202 represents a significant step in Senti Bio's clinical development, indicating progress in its research and development initiatives [3]

[PART I - FINANCIAL INFORMATION](index=4&type=section&id=PART%20I%20-%20FINANCIAL%20STATEMENTS) [Financial Statements (Unaudited)](index=4&type=section&id=Item%201.%20FINANCIAL%20STATEMENTS%20(UNAUDITED)) Senti Biosciences reported a $28.8 million net loss for H1 2025, with cash decreasing to $21.6 million, raising substantial doubt about its going concern ability [Condensed Consolidated Balance Sheets](index=5&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) Total assets decreased to $68.5 million by June 30, 2025, driven by a 55.3% reduction in cash and cash equivalents to $21.6 million Condensed Consolidated Balance Sheet Highlights (in thousands) | Account | June 30, 2025 | December 31, 2024 | | :--- | :--- | :--- | | **Assets** | | | | Cash and cash equivalents | $21,576 | $48,277 | | Total current assets | $32,521 | $58,961 | | TOTAL ASSETS | $68,540 | $97,841 | | **Liabilities & Equity** | | | | Total current liabilities | $9,987 | $13,146 | | TOTAL LIABILITIES | $43,888 | $47,086 | | TOTAL STOCKHOLDERS' EQUITY | $24,652 | $25,649 | - Cash and cash equivalents decreased by **55.3%** from **$48.3 million** at the end of 2024 to **$21.6 million** as of June 30, 2025[9](index=9&type=chunk) [Condensed Consolidated Statements of Operations and Comprehensive Loss](index=6&type=section&id=Condensed%20Consolidated%20Statements%20of%20Operations%20and%20Comprehensive%20Loss) Net loss widened to $28.8 million for H1 2025, up from $23.3 million in H1 2024, primarily due to increased R&D and G&A expenses Statement of Operations Summary (in thousands) | Metric | Q2 2025 | Q2 2024 | Six Months 2025 | Six Months 2024 | | :--- | :--- | :--- | :--- | :--- | | Research and development | $10,029 | $9,151 | $19,310 | $17,929 | | General and administrative | $6,769 | $4,205 | $13,885 | $11,728 | | Loss from operations | $(16,798) | $(13,356) | $(33,195) | $(29,657) | | Net loss | $(14,733) | $(11,203) | $(28,845) | $(23,314) | | Net loss per share | $(0.56) | $(2.45) | $(1.59) | $(5.10) | [Condensed Consolidated Statements of Stockholders' Equity](index=7&type=section&id=Condensed%20Consolidated%20Statements%20of%20Stockholders%27%20Equity) Stockholders' equity decreased to $24.7 million by June 30, 2025, with all Series A preferred stock converting to common stock and accumulated deficit reaching $326.0 million - In the first quarter of 2025, all outstanding Series A redeemable convertible preferred stock (**21,157 shares**) was converted into **21,157,000 shares** of common stock[13](index=13&type=chunk)[76](index=76&type=chunk) - The accumulated deficit increased by **$28.9 million** during the first six months of 2025, reaching **$326.0 million**[9](index=9&type=chunk)[13](index=13&type=chunk) [Condensed Consolidated Statements of Cash Flows](index=9&type=section&id=Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) Net cash used in operating activities increased to $27.1 million for H1 2025, resulting in a $26.7 million net decrease in cash and equivalents Cash Flow Summary (in thousands) | Activity | Six Months 2025 | Six Months 2024 | | :--- | :--- | :--- | | Net cash used in operating activities | $(27,123) | $(20,027) | | Net cash used in investing activities | $(184) | $(15) | | Net cash provided by financing activities | $597 | $0 | | **Net decrease in cash** | **$(26,710)** | **$(20,042)** | [Notes to Condensed Consolidated Financial Statements](index=10&type=section&id=Notes%20to%20Condensed%20Consolidated%20Financial%20Statements) Notes disclose substantial doubt about going concern due to insufficient cash, detailing the GeneFab transaction, leases, stock compensation, and related party dealings - The company concluded that substantial doubt exists about its ability to continue as a going concern, as its cash and cash equivalents of **$21.6 million** as of June 30, 2025, are not sufficient to fund operations for at least one year[24](index=24&type=chunk) - On March 20, 2025, the company entered into an at-the-market (ATM) offering agreement to sell up to **$17.5 million** of its common stock. Through June 30, 2025, it sold **155,840 shares** for gross proceeds of **$0.6 million**[70](index=70&type=chunk) - The company has significant related party transactions, primarily with GeneFab, LLC, which provides manufacturing services and subleases facilities from Senti. As of June 30, 2025, Senti had a **$5.5 million** prepaid expense balance and a **$3.5 million** receivable from GeneFab[30](index=30&type=chunk)[38](index=38&type=chunk) [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=27&type=section&id=Item%202.%20MANAGEMENT%27S%20DISCUSSION%20AND%20ANALYSIS%20OF%20FINANCIAL%20CONDITION%20AND%20RESULTS%20OF%20OPERATIONS) Management discusses clinical-stage biotech status, recent developments including SENTI-202 Orphan Drug Designation and SN301A trial halt, and reiterates going concern doubts due to insufficient cash - The company's lead product candidate, SENTI-202, received **Orphan Drug Designation** from the FDA for treating relapsed/refractory hematologic malignancies[140](index=140&type=chunk) - Enrollment in the clinical trial for SN301A, which incorporates Senti's SENTI-301A gene circuit, was stopped by partner Celest Therapeutics due to the observation of dose-limiting toxicities[123](index=123&type=chunk)[141](index=141&type=chunk) - Management concluded there is substantial doubt about the company's ability to continue as a going concern, as cash and cash equivalents of **$21.6 million** as of June 30, 2025, are not sufficient to fund operations for at least one year[185](index=185&type=chunk) Comparison of Operating Results (in thousands) | Period | R&D Expense | G&A Expense | Net Loss | | :--- | :--- | :--- | :--- | | **Q2 2025** | $10,029 | $6,769 | $(14,733) | | **Q2 2024** | $9,151 | $4,205 | $(11,203) | | **Six Months 2025** | $19,310 | $13,885 | $(28,845) | | **Six Months 2024** | $17,929 | $11,728 | $(23,314) | [Quantitative and Qualitative Disclosures About Market Risk](index=40&type=section&id=Item%203.%20QUANTITATIVE%20AND%20QUALITATIVE%20DISCLOSURES%20ABOUT%20MARKET%20RISK) As a smaller reporting company, Senti Biosciences is exempt from providing quantitative and qualitative market risk disclosures - As a "smaller reporting company," Senti Biosciences is not required to provide quantitative and qualitative disclosures about market risk[195](index=195&type=chunk) [Controls and Procedures](index=41&type=section&id=Item%204.%20CONTROLS%20AND%20PROCEDURES) Management concluded disclosure controls were effective as of June 30, 2025, having remediated a previously identified material weakness in finance and accounting resources - A material weakness in internal control over financial reporting, related to insufficient resources in the finance and accounting function, was previously identified[198](index=198&type=chunk) - Management believes the previously identified material weakness has been remediated as of June 30, 2025, and concluded that disclosure controls and procedures were effective[199](index=199&type=chunk) [PART II - OTHER INFORMATION](index=43&type=section&id=PART%20II%20-%20OTHER%20INFORMATION) [Legal Proceedings](index=43&type=section&id=Item%201.%20LEGAL%20PROCEEDINGS) The company is not aware of any material legal proceedings or claims that would adversely affect its operations or financial condition - The company reports no material legal proceedings[203](index=203&type=chunk) [Risk Factors](index=43&type=section&id=Item%201A.%20RISK%20FACTORS) Key risks include recurring losses, going concern doubts, unproven gene circuit technology, SN301A trial halt, reliance on GeneFab, and IP protection challenges - The company has a history of recurring losses and its financial condition raises substantial doubt about its ability to continue as a going concern, requiring it to obtain sufficient funding[205](index=205&type=chunk)[212](index=212&type=chunk) - The company's gene circuit platform is a novel, unproven technology, which makes it difficult to predict the time and cost of development and the potential for regulatory approval[206](index=206&type=chunk)[248](index=248&type=chunk) - There are significant risks related to the transaction with GeneFab, including potential failure to realize anticipated benefits and GeneFab's non-payment of approximately **$3.5 million** in sublease and service obligations as of June 30, 2025[283](index=283&type=chunk)[306](index=306&type=chunk)[315](index=315&type=chunk) - Clinical trials may fail or suffer delays. The SN301A trial was stopped due to dose-limiting toxicities, and SENTI-202, the lead candidate, is still in early clinical development[205](index=205&type=chunk)[246](index=246&type=chunk) [Unregistered Sales of Equity Securities and Use of Proceeds](index=119&type=section&id=Item%202.%20UNREGISTERED%20SALES%20OF%20EQUITY%20SECURITIES%20AND%20USE%20OF%20PROCEEDS) The company reported no unregistered sales of equity securities during the period - None[558](index=558&type=chunk) [Defaults Upon Senior Securities](index=119&type=section&id=Item%203.%20DEFAULTS%20UPON%20SENIOR%20SECURITIES) The company reported no defaults upon senior securities - None[559](index=559&type=chunk) [Mine Safety Disclosures](index=119&type=section&id=Item%204.%20MINE%20SAFETY%20DISCLOSURES) This item is not applicable to the company - None[560](index=560&type=chunk) [Other Information](index=119&type=section&id=Item%205.%20OTHER%20INFORMATION) No directors or officers adopted or terminated Rule 10b5-1 trading plans during the quarter ended June 30, 2025 - No directors or officers adopted or terminated any Rule 10b5-1 trading plans during the quarter[561](index=561&type=chunk) [Exhibits](index=120&type=section&id=Item%206.%20EXHIBITS) This section lists exhibits filed with the quarterly report, including officer certifications and Inline XBRL data files

[Management Commentary](index=1&type=section&id=Management%20Commentary) The CEO highlighted significant progress in the SENTI-202 clinical trial, including the completion of dose finding and confirmation of the recommended Phase 2 dose (RP2D), with additional efficacy and durability data anticipated by the end of 2025 - Completed dose finding and confirmed the recommended Phase 2 dose (RP2D) for the SENTI-202 Phase 1 study[2](index=2&type=chunk) - Currently enrolling additional relapsed/refractory AML patients in the dose expansion phase at the RP2D[2](index=2&type=chunk) - Expects to release additional efficacy and durability data from the ongoing Phase 1 study in Q4 2025[1](index=1&type=chunk)[2](index=2&type=chunk) [Recent Pipeline and Corporate Updates](index=1&type=section&id=Recent%20Pipeline%20and%20Corporate%20Updates) Senti Bio has made notable progress with its lead program, SENTI-202, securing FDA Orphan Drug Designation and additional grant funding, while strengthening leadership and increasing market awareness [SENTI-202 Program Highlights](index=1&type=section&id=SENTI-202%20Program%20Highlights) - The dose finding phase for the Phase 1 clinical trial of SENTI-202 (NCT06325748) for hematologic malignancies including AML is complete, and the recommended Phase 2 dose (RP2D) has been confirmed[5](index=5&type=chunk) - The U.S. FDA granted **Orphan Drug Designation** for the use of SENTI-202 to treat Acute Myeloid Leukemia (AML)[5](index=5&type=chunk) - Received an additional **$1.0 million** tranche from a California Institute for Regenerative Medicines (CIRM) grant to advance the clinical development of SENTI-202[5](index=5&type=chunk) [Corporate Developments and Market Awareness](index=1&type=section&id=Corporate%20Developments%20and%20Market%20Awareness) - Strengthened leadership with the appointment of Bryan Baum to the Board of Directors and Dr. James B. Trager to the Scientific Advisory Board[5](index=5&type=chunk) - Increased visibility through participation in various events, including Nasdaq's Amplify Spotlight Series, the 2025 SEED Conference, and virtual investor webinars hosted by Chardan and Webull[5](index=5&type=chunk)[9](index=9&type=chunk) [Second Quarter 2025 Financial Results](index=2&type=section&id=Second%20Quarter%202025%20Financial%20Results) For the second quarter of 2025, Senti Bio reported a net loss of $14.7 million and held $21.6 million in cash and cash equivalents, with operating expenses increasing due to higher R&D and G&A costs Key Financial Metrics (Q2 2025 vs Q2 2024) | Metric | Q2 2025 | Q2 2024 | Change | | :--- | :--- | :--- | :--- | | R&D Expenses | $10.0 million | $9.2 million | +$0.8 million | | G&A Expenses | $6.8 million | $4.2 million | +$2.6 million | | Net Loss | $14.7 million | $11.2 million (from table) | +$3.5 million | | Net Loss per Share | $0.56 | $2.45 (from table) | N/A (share count changed) | Cash Position | Date | Cash and Cash Equivalents | | :--- | :--- | | June 30, 2025 | $21.6 million | | December 31, 2024 | $48.3 million | - The increase in R&D expenses was primarily due to a **$0.8 million** rise in external services and supplies costs[9](index=9&type=chunk) - The increase in G&A expenses was mainly driven by a **$2.5 million** increase in personnel-related expenses[9](index=9&type=chunk) [Financial Statements](index=5&type=section&id=Financial%20Statements) The unaudited financial statements provide a detailed view of Senti Bio's financial position as of June 30, 2025, and its operational results for the three and six months then ended, showing a decrease in cash and total assets since year-end 2024 [Unaudited Selected Consolidated Balance Sheet Data](index=5&type=section&id=Unaudited%20Selected%20Consolidated%20Balance%20Sheet%20Data) Consolidated Balance Sheet Data (in thousands) | | June 30, 2025 | December 31, 2024 | | :--- | :--- | :--- | | **Cash and cash equivalents** | **$21,576** | **$48,277** | | Total assets | $68,540 | $97,841 | | Total liabilities | $43,888 | $47,086 | | Accumulated deficit | $(325,979) | $(297,134) | | Total stockholders' equity | $24,652 | $25,649 | [Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss](index=6&type=section&id=Unaudited%20Condensed%20Consolidated%20Statements%20of%20Operations%20and%20Comprehensive%20Loss) Condensed Consolidated Statements of Operations (in thousands, except per share data) | | Three Months Ended June 30, | Six Months Ended June 30, | | :--- | :--- | :--- | | | **2025** | **2024** | **2025** | **2024** | | **Operating Expenses** | | | | | | Research and development | $10,029 | $9,151 | $19,310 | $17,929 | | General and administrative | $6,769 | $4,205 | $13,885 | $11,728 | | **Total operating expenses** | **$16,798** | **$13,356** | **$33,195** | **$29,657** | | Loss from operations | $(16,798) | $(13,356) | $(33,195) | $(29,657) | | Total other income | $2,065 | $2,153 | $4,350 | $6,343 | | **Net loss** | **$(14,733)** | **$(11,203)** | **$(28,845)** | **$(23,314)** | | **Net loss per share** | **$(0.56)** | **$(2.45)** | **$(1.59)** | **$(5.10)** |